Left Atrial Appendage Closure: Past, Present, and Future.

Q3 Medicine
Journal of Innovations in Cardiac Rhythm Management Pub Date : 2026-09-15 eCollection Date: 2026-09-01 DOI:10.19102/icrm.2026.17095
Elio Zito, Pamela Horton Embrey, Vincenzo Mirco La Fazia, Carola Gianni, Sanghamitra Mohanty, Claudio Tondo, Andrea Natale, Rodney Horton
{"title":"Left Atrial Appendage Closure: Past, Present, and Future.","authors":"Elio Zito, Pamela Horton Embrey, Vincenzo Mirco La Fazia, Carola Gianni, Sanghamitra Mohanty, Claudio Tondo, Andrea Natale, Rodney Horton","doi":"10.19102/icrm.2026.17095","DOIUrl":null,"url":null,"abstract":"<p><p>Left atrial appendage closure (LAAC) has emerged as an important alternative strategy for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), particularly when long-term oral anticoagulation (OAC) is contraindicated or poorly tolerated. Initially developed as a surgical technique based on ligation or excision of the left atrial appendage, LAAC has progressively shifted toward refined, minimally invasive transcatheter approaches. Randomized and observational data have established non-inferiority to warfarin, and non-inferiority compared with direct oral anticoagulants has also been suggested in selected high-risk cohorts and is currently under prospective evaluation in pivotal trials. At the same time, indications for LAAC are expanding beyond the classical high-bleeding-risk population, now encompassing patients undergoing atrial fibrillation (AF) ablation and those with only moderate thromboembolic risk but intolerance to OAC. Parallel advances in device design aimed at improving anatomical conformability, sealing performance, and surface biocompatibility seek to reduce peri-device leak (PDL), device-related thrombus (DRT), and bleeding and may allow for simplified or shortened post-procedural antithrombotic regimens. This narrative review summarizes the historical evolution of LAAC from surgical to contemporary transcatheter solutions, outlines key clinical evidence versus medical therapy, and discusses emerging implant-based and implant-free technologies. As evidence accumulates from ongoing randomized controlled trials, LAAC may transition from a niche intervention to a more widely adopted, guideline-supported component of AF management. However, broader implementation will depend on robust demonstration of long-term safety and efficacy, including clarification of PDL-, DRT-, and bleeding-related trade-offs, to define when LAAC can serve not only as an alternative to OAC but also as a tailored option for selected NVAF patients.</p>","PeriodicalId":36299,"journal":{"name":"Journal of Innovations in Cardiac Rhythm Management","volume":"17 9","pages":"6874-6895"},"PeriodicalIF":0.0000,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668054/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Innovations in Cardiac Rhythm Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19102/icrm.2026.17095","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Left atrial appendage closure (LAAC) has emerged as an important alternative strategy for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), particularly when long-term oral anticoagulation (OAC) is contraindicated or poorly tolerated. Initially developed as a surgical technique based on ligation or excision of the left atrial appendage, LAAC has progressively shifted toward refined, minimally invasive transcatheter approaches. Randomized and observational data have established non-inferiority to warfarin, and non-inferiority compared with direct oral anticoagulants has also been suggested in selected high-risk cohorts and is currently under prospective evaluation in pivotal trials. At the same time, indications for LAAC are expanding beyond the classical high-bleeding-risk population, now encompassing patients undergoing atrial fibrillation (AF) ablation and those with only moderate thromboembolic risk but intolerance to OAC. Parallel advances in device design aimed at improving anatomical conformability, sealing performance, and surface biocompatibility seek to reduce peri-device leak (PDL), device-related thrombus (DRT), and bleeding and may allow for simplified or shortened post-procedural antithrombotic regimens. This narrative review summarizes the historical evolution of LAAC from surgical to contemporary transcatheter solutions, outlines key clinical evidence versus medical therapy, and discusses emerging implant-based and implant-free technologies. As evidence accumulates from ongoing randomized controlled trials, LAAC may transition from a niche intervention to a more widely adopted, guideline-supported component of AF management. However, broader implementation will depend on robust demonstration of long-term safety and efficacy, including clarification of PDL-, DRT-, and bleeding-related trade-offs, to define when LAAC can serve not only as an alternative to OAC but also as a tailored option for selected NVAF patients.

左心耳闭合:过去、现在和将来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Innovations in Cardiac Rhythm Management
Journal of Innovations in Cardiac Rhythm Management Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.50
自引率
0.00%
发文量
70
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书